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 Abstract 
Many previous reports have documented a relationship between metabolic 
syndrome, in terms of insulin resistance, and colorectal cancer. However, the 
association of insulin resistance with colorectal adenoma has not been 
investigated in detail. To elucidate the association of metabolic syndrome 
components and insulin resistance with adenoma, homeostasis model 
assessment insulin resistance (HOMA-IR) and metabolic syndrome were 
investigated in individuals with adenoma. A cross-sectional study was 
conducted involving individuals who underwent scheduled health 
examinations using total colonoscopy. Total 963 males and 306 females were 
investigated. Male and female subjects comprised controls 702 and 260, 
individuals with adenoma 261 and 46, respectively. HOMA-IR was 
categorized into three groups as follows; normal (<1.6), intermediate (>1.6 - 
<2.5), and insulin resistance (≥2.5). Metabolic syndrome was defined by a 
combination of any three of the following components: central obesity (waist 
circumference >90 cm in men, 80 cm in women); elevated blood pressure 
(systolic blood pressure >130 mmHg and/or diastolic blood pressure >85 
mmHg); elevated fasting plasma glucose (>100 mg/dL); reduced high-density 
lipoprotein-cholesterol (<40 mg/dL in men, <50 mg/dL in women); elevated 
triglyceride (>150 mg/dL). Only in male subjects, multivariate analysis of 
HOMA-IR showed that the intermediate and insulin resistance groups had a 
significantly increased risk for colorectal adenoma, even after adjustment for 
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waist circumference (odds ratio, 1.62 and 2.23; 95% confidence interval, 
1.07-2.45 and 1.31-3.79, respectively). Accumulation of any metabolic 
syndrome components increased the risk of colorectal adenoma (P-trend 
=0.001). However, none of the components alone demonstrated a significant 
risk for colorectal adenoma. In female, no any significant risk was detected 
except component of triglyceride under the condition that evaluated by 
multivariate analysis. Our data indicate that an increased level of HOMA-IR 
is a significant risk factor for colorectal adenoma in Japanese males, 
surpassing any individual component of metabolic syndrome. 
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Introduction 
Colorectal cancer is one of the most common cancers worldwide. It has 
already been shown that obesity (Frezza et al. 2002; Moghaddam et al. 2007), 
abdominal obesity (Pischon et al. 2006), insulin resistance (Giovannucci 
1995; Colangelo et al. 2002; Trevisan et al. 2001) and metabolic syndrome 
(Cowey and Hardy 2006; Ahmed et al. 2006) are associated with colorectal 
cancer. 
In the late 1990s, colorectal cancer started to increase rapidly in Japan (Yui 
et al. 2004), and currently it is the third leading cause of cancer death in 
Japanese males and the leading cause in Japanese females (Center for 
Control and Information Services, National Cancer Center, Japan). To reduce 
the incidence and mortality of colorectal cancer, it is necessary to prevent, 
find, and treat colorectal adenomas, which are the established precursor 
lesions of colorectal cancer. Therefore, it is important to elucidate the risk 
factors for colorectal adenoma. Recently, the reported relationship between 
colorectal cancer and metabolic syndrome has drawn considerable attention 
(Stocks et al. 2008; Omata et al. 2009). Moreover, some studies have shown 
that metabolic syndrome is a risk factor for colorectal adenoma (Morita et al. 
2005; Kim et al. 2007). Among the components of metabolic syndrome, waist 
circumference was shown to be that most strongly associated with colorectal 
adenoma (Kim et al. 2007; Lee et al. 2008), whereas the influences of plasma 
glucose, lipids and blood pressure appear to vary (Ashbeck et al. 2009; Lui et 
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al. 2010). 
Previously, in a study involving a small population, we demonstrated that 
homeostasis model assessment insulin resistance (HOMA-IR) had a positive 
association with the incidence of colorectal adenoma (Otake et al. 2005). 
HOMA-IR has been suggested that it’s a method to estimate insulin 
resistance from the fasting glucose and insulin concentrations. HOMA-IR is 
a useful model to give us the information about degree of insulin resistance 
only from fasting blood samples, so this index thought to be valid in 
epidemiological studies （Haffner et al. 1997）. Unfortunately, only a few 
subsequent studies have addressed the significance of HOMA-IR as a risk 
factor for colorectal adenoma （Kang et al. 2010; Yamamoto et al. 2010）. 
Therefore, in the present study, we evaluated the significance of HOMA-IR as 
a risk factor for colorectal adenoma in a large population representing that of 
Japan as a whole. In addition to HOMA-IR, we investigated the relationship 
of metabolic syndrome and its individual components with colorectal 
adenoma, to determine which factors are significant. 
 
Methods and procedures 
Study population 
We studied a consecutive series of subjects who underwent a health 
examination, including colonoscopy, for school teachers and staff at the 
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Tohoku Central Hospital for Public School Teachers, Yamagata, Japan, 
between June 2008 and January 2010. This study was approved by the ethics 
committee of Tohoku Central Hospital. Among the individuals examined 
during this period, 1,667 agreed to participate in our study. Because 15 
participants canceled their colonoscopy, we enrolled 1,652 participants. We 
then excluded patients for whom any of the following criteria applied: a) a 
history of colorectal polypectomy (n=298), b) incomplete colonoscopy (n=31), 
c) history or presence of malignant neoplasms (n=50), d) chronic 
inflammatory diseases such as collagen disease (n=6), c) inflammatory bowel 
disease (n=2), e) history of proctocolectomy (n=14), and f) treatment with 
insulin (n=1). After the subjects had undergone colonoscopy, the 
colonoscopists reported the features observed, including the location, size, 
and number of adenomas, hyperplastic polyps, and other benign lesions. 
Adenomas were diagnosed by endoscopical observation with white light and 
dye method. The final diagnosis was checked by another colonoscopist at 
Tohoku Central Hospital. In this health examination program, endoscopic 
treatment for colorectal adenoma was not allowed, so we were unable to 
collect any pathological information about the polyps observed. We assessed 
only adenomas in this study, because they are well known to be precursors of 
colorectal cancer. Two were excluded because of incomplete data collection 
with regard to blood samples and the characteristics of adenomas, 
respectively. Therefore, a total of 383 participants were excluded. Finally, 963 
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males and 306 females remained. Male and female subjects comprised 
controls 702 and 260, cases with adenoma 261 and 46, respectively.  
Covariate assessment 
Participants were encouraged to answer a self-administered questionnaire 
about alcohol intake, smoking habits, family medical history, past disease, 
current disease, medication, and history of colorectal polyps or colorectal 
polypectomy. In this health examination, participants were questioned about 
smoking status (never, past, current) and daily number of cigarettes 
consumed, and the interval since cessation of smoking among ever-smokers. 
Questions about medical history were also asked, including both use of 
therapeutic and recreational drugs, and previous surgery. Consumption of 
alcoholic beverages was converted to the amount of ethanol with reference to 
a previous study (Okamura et al. 2004). The amount of alcohol consumed 
(g/day) was estimated, and pack-year values calculated for cigarette 
consumption. One pack-year was defined as the smoking of 20 cigarettes 
daily for 1 year. We also asked whether participants had a first-degree family 
history of colorectal cancer. Menopause was asked to female subjects, 
additionally. 
 
Anthropometric measurements 
Anthropometric variables were measured by well-trained examiners. Before 
colonoscopy, body weight and height were measured, and body mass index 
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(BMI) was calculated as the weight in kilograms divided by the height in 
meters squared. Waist circumference was measured in the horizontal plane 
at the level of the umbilicus. Sitting blood pressure was also measured. 
 
Clinical and laboratory data 
Venous blood samples were drawn after an overnight fast to determine the 
levels of serum lipids and other biochemical parameters. Serum fasting 
plasma glucose, hemoglobin A1c (HbA1c), fasting insulin, high-density 
lipoprotein-cholesterol (HDL-cholesterol), low-density lipoprotein-cholesterol 
(LDL-cholesterol), triglycerides and uric acid were assayed in the hospital 
laboratory. HOMA-IR was calculated as the fasting glucose (mg/dL) × fasting 
insulin (μU/mL) / 405 (Matthews et al. 1985). 
In the classification study, HOMA-IR was used to categorize patients into 
three groups: a normal group (<1.6), an intermediate group (>1.6 - <2.5), and 
a true insulin resistance group (≥2.5), according to the criteria proposed by 
the Japan Diabetes Society (The Japan Diabetes Society 2010).  
 
Diagnostic criteria for metabolic syndrome 
To evaluate the association of metabolic syndrome with adenoma, we used 
the classification of metabolic syndrome established in 2009 as a result of 
harmonization of the two common definitions proposed by the American 
Heart Association/National Heart, Lung and Blood Institute and the 
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International Diabetes Federation (Alberti et al. 2009). This harmonized 
definition of metabolic syndrome includes a combination of any three of the 
following components: central obesity (waist circumference >90 cm in men, 80 
cm in women); elevated blood pressure (systolic blood pressure >130 mmHg 
and/or diastolic blood pressure >85 mmHg or treatment for previously 
diagnosed hypertension); an elevated fasting plasma glucose level (>100 
mg/dL) or receiving drug treatment for elevated glucose; a reduced HDL 
cholesterol level (<40 mg/dL in men, <50mg/dL in women) or receiving 
specific treatment for this disorder; an elevated triglyceride level (>150 
mg/dL) or receiving specific treatment for this disorder. Central obesity was 
defined on the basis of population- and country-specific criteria, and the 
cut-off point for central obesity was that for Asians proposed by the 
International Diabetes Federation Task Force Metabolic Syndrome Criteria 
2005 (Alberti et al. 2005). 
 
Statistical analysis  
 All statistical analyses were performed using the SPSS version 11.0J 
software package (SPSS Inc. Tokyo, Japan). Chi-squared test was used for 
comparison of discrete variables, and the Mann-Whitney U-test for 
comparison of continuous variables. A two-tailed P value of <0.05 was 
considered statistically significant. The continuous variables measured in 
this study were expressed as the means ± standard deviation, and categorical 
10 
 
variables were expressed as the number (%). Multivariate analysis was 
performed using logistic regression and adjusted by age, pack-year value, 
mean daily alcohol consumption, first-degree familial history of colorectal 
cancer, and use of therapeutic drugs. At multivariate analysis in female, 
menopause was also added. For each variable, the odds ratio (OR), 95% 
confidence interval (95% CI), and P-value were calculated.  
 
Results 
Background characteristics, anthropometric index and biochemical markers 
Table 1 shows the characteristics of adenoma cases and controls in male 
subjects. Individuals with adenoma were significantly older than the controls. 
However, familial history of colorectal cancer, pack-year value, and mean 
daily alcohol consumption did not differ significantly between the groups. The 
rate of drug use also showed no significant inter-group difference. Individuals 
with adenoma had a significantly higher body mass index, waist 
circumference, systolic blood pressure, fasting plasma glucose level, HbA1c, 
insulin, HOMA-IR, and triglycerides. Table 2 shows the characteristics of 
adenoma cases and controls in female subjects. Individuals with adenoma 
had significant higher menopause rate and uric acid. 
 
Odds ratios for the three categories of HOMA-IR 
Table 3 and 4 show division of the patients into three categories based on 
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HOMA-IR to evaluate the risk of colorectal adenoma. In male, the >1.6-<2.5 
(intermediate) and ≥2.5 (true resistance) categories of HOMA-IR were 
associated with a significant risk even after adjustment for age, familial 
history of colorectal adenoma, pack-year value, mean daily ethanol 
consumption, treatment for diabetes mellitus, use of aspirin/non-steroidal 
anti-inflammatory drugs (NSAIDs), and waist circumference (OR, 1.61; 95% 
CI, 1.06-2.44; P-value, 0.024 and OR, 2.22; 95% CI, 1.30-3.77; P-value, 0.003, 
respectively). On the other hand, all HOMA-IR categories indicated no any 
significant risk in female (Table 4).  
 
HOMA-IR, glucose, and insulin characteristics of individuals with adenoma 
in male subjects  
We evaluated HOMA-IR, glucose, and insulin in relation to characteristics of 
adenoma in male and female subjects (Table 5 & Table 6). HOMA-IR was 
slightly higher in individuals with adenoma in both the right and left sides of 
the colon than in either side of the colon alone, and with an adenoma size 
exceeding 10 mm, but the differences were not significant. The number of 
adenomas was not related to HOMA-IR. The fasting plasma glucose level was 
not associated with adenoma location, size or number. However, the fasting 
insulin level was significantly higher in individuals with large adenomas. 
Adenoma cases of female subjects showed inverse association the size of 
adenoma. HOMA-IR and Insulin were smaller revel in >10 mm group 
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compared with small adenoma group.  
 
Metabolic syndrome-associated colorectal adenoma 
Table 7 shows the various components of the harmonized metabolic 
syndrome criteria for colorectal adenoma in male. When the individual 
components were analyzed separately, none of component demonstrated a 
significant association with colorectal adenoma risk in male. Table 8 also 
showed analysis of individual components of metabolic syndrome in female. 
The component of elevated triglyceride had significant risk for colorectal 
adenoma only by multivariate analysis (OR, 3.19; 95% CI, 1.19-8.51; P-value, 
0.021).  
The male subjects with metabolic syndrome had a significantly higher risk 
for colorectal adenoma, as shown in Table 9 (OR, 1.67; 95% CI, 1.19-2.36; 
P-value, 0.003). Subjects who had more than three or four components of 
metabolic syndrome had a higher risk, and the risk was increased in patients 
with three or four compared with those who had none (OR, 1.69; 95% CI, 1.03 
-2.77; P-value, 0.036 and OR 2.23; 95% CI 1.28-3.88; P-value, 0.005, 
respectively, P-trend =0.001). On the other hand female had none of the 
association with colorectal adenoma and metabolic syndrome diagnosis and 
the number of components (Table 10). 
 
Discussion 
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The HOMA-IR was proposed on the basis of the results of the normal 
glucose clump test, the product of the fasting plasma glucose level and the 
insulin level being inversely associated with glucose intake (Matthews et al. 
1985). This index is generally used to reflect insulin resistance, and is 
thought to be the most useful index for health assessment in a large number 
of subjects. Previously, many studies have evaluated the relationship 
between colorectal adenoma and glucose metabolism-related factors such as 
hyperglycemia, hyperinsulinemia, increased levels of insulin-like growth 
factor (IGF)-1, and decreased levels of IGF binding protein-3 (Giovannucci et 
al. 2000; Renehan et al. 2001; Marugame et al. 2002). However, only a few 
studies applying HOMA-IR have been reported. In the present study, we 
revealed that HOMA-IR was a significant risk factor for colorectal adenoma, 
and moreover this represented the first application of HOMA-IR categorized 
according to the Japanese insulin resistance classification. The OR of the true 
resistance group relative to the normal group was 2.23. Previous study 
indicated high level of IGF-1 and low levels of IGFBP-3 were associated with 
an elevated risk of adenoma (Giovannucci et al. 2000). Kang et al. reported 
that the OR of the highest HOMA-IR group relative to the lowest group in 
five categories was increased significantly to 1.99 (Kang et al. 2010). In 
contrast, Yamamoto et al. reported that the mean value of HOMR-IR in 
patients with adenoma was not different from that in controls, and that 
HOMA-IR was not a risk factor for colorectal adenoma (Yamamoto et al. 
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2010). They described that highly rate of smoker might ascribed no 
association of visceral adiposity area and colorectal adenoma. Cigarette is 
well known having strong effect for decrease body weight (Mizoue et al. 1998 
0) and also association for colorectal adenoma. In fact Adenoma cases 
indicated lower level in factors of abdominal obesity and also of insulin 
resistance. We indicated that association of 8-hydroxy-2'-deoxyguanosine 
(8-OHdG) which is the marker of systematic oxidative stress and colorectal 
adenoma (Sato, et al. 2010). Smoking is one of the causes of oxidative stress, 
and increases 8-OHdG level (Campos et al. 2011; Morita et al. 2005). 
Oxidative stress might more affect for incidence of colorectal adenoma than 
abdominal obesity and insulin resistance in their study.  
We also evaluated the relationship of HOMA-IR to the location, size and 
number of colorectal adenomas. Individuals with adenomas over 10 mm in 
size showed a significantly higher insulin level, but not a higher HOMA-IR. 
Adenomas learned toward <10mm, >10mm group was so small. This might 
have accounted for the large difference in the insulin level between the two 
groups. However, it is known that an increased insulin level prevents 
apoptosis of colorectal tumors (Keku et al. 2005). As the present study did not 
involve a pathological assessment of colorectal adenomas, we were unable to 
investigate the relationship between HOMA-IR and advanced adenomas, 
which have been described as colorectal polyps >10 mm in diameter and/or 
villous components and/or severe dysplasia, which have high malignant 
15 
 
potential (Winawer et al. 1993; Zarchy and Ershoff 1994). Therefore our 
evaluation was limited to only the size of advanced adenomas. On the other 
hand women indicated inverse association advanced adenoma with 
HOMA-IR and insulin compared with male cases. Large adenoma cases were 
just only two cases. So father investigation with more cases of large adenoma 
is needed to evaluate the certain relation in females.  
The present study also revealed that metabolic syndrome is a risk factor for 
colorectal adenoma. The OR for patients with metabolic syndrome relative to 
controls was 1.67, which was similar to the values reported in other studies 
(Morita et al. 2005; Kim et al. 2007; Lui et al. 2010). In addition to metabolic 
syndrome itself, Wang et al. reported that accumulation of a number of 
components of metabolic syndrome led to an increasing risk of colorectal 
adenoma, according to the NCEP-ATPIII diagnostic criteria (Wang et al. 
2005). Their evaluation was conducted using rectosigmoidscopy. However, 
Lee et al. obtained similar results using total colonoscopy in male subjects 
(Lee et al. 2008). In contrast, Tsilidis et al. did not find any relationship 
between an accumulated number of metabolic syndrome components and an 
increased risk of adenoma (Tsilidis et al. 2010). However, their evaluation 
was a cohort study, and the population was relatively small, including 132 
controls and 260 individuals with adenoma. In the present study we clearly 
revealed that an accumulated number of components of metabolic syndrome 
were associated with an increased risk of colorectal adenoma. 
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We were also interested in which component(s) of metabolic syndrome most 
strongly influenced the risk of colorectal adenoma. Most studies have 
reported that waist circumference is a significant risk factor in itself 
(Martikainen and Marmot 1999; Kim et al. 2007; Ashbeck et al. 2009; Nam et 
al. 2010; Yamamoto et al. 2010). However, we did not find any significant 
relationship with waist circumference in males. Although we applied the 
Asian criteria for waist circumference (>90 cm) (Alberti et al. 2005), we also 
applied the Japanese criteria (>85 cm) (Japanese Committee of the Metabolic 
Syndrome Diagnostic Criteria 2005) and obtained similar results (data not 
shown). Kang and Sass investigated visceral fat area as a significant risk 
factor for colorectal adenoma, and also reported that waist circumference and 
subcutaneous fat did not show a constant relationship (Kang et al. 2010; Sass 
et al. 2004). Tsilidis also reported that there was no relationship between 
BMI and adenoma in their cohort study (Tsilidis et al. 2010). Although the 
relationship between visceral fat area and colorectal adenoma appears to be 
undeniable, any association with waist circumference, subcutaneous fat or 
BMI remains to be clarified. 
In this current study, female was indicated to have no association for 
colorectal adenoma in both highly HOMA-IR and metabolic syndrome 
diagnosis. Previous studies showed that female had less age-adjusted 
incidence for colorectal cancer than male (Tamura, et al 1996; Ji et al. 1998; 
Sung 2005). Huang also reported female reduce the risk for colorectal 
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adenoma compared with male (Huang et al. 2010). This reduction has 
interpreted by the protection effects of sex hormones. Certain mechanism has 
not been clear yet, but several studies indicate that reproductive agents such 
age of menarche, age of menopause and estrogen replacement therapy 
associated with colorectal cancer (Crandall 1999; Grodstein, et al. 1998). 
Protective effects for colorectal adenoma also reported but not consistently 
than for colorectal cancer. Consequently the association with colorectal 
adenoma and HOMA-IR or metabolic syndrome might hardly reveal. Further 
study is needed for evaluate association of colorectal adenoma and several 
factors of reproductive agents. 
Only component of elevated triglyceride assessed by multivariate analysis 
was a significant risk for colorectal adenoma in female. But the t-test and 
univariat analysis had not demonstrated any significance of triglycerides. 
Only few previous studies indicated the association of hyper triglyceride and 
colorectal adenoma (Kang et al. 2010; Liu et al. 2010).  If this result doesn’t 
contradict previous report, triglycerides is thought to have a limited 
association from our study. Additionally Lui evaluated elevated triglyceride 
component of metabolic syndrome in men and women respectively, no 
significant association of elevated triglyceride and colorectal adenoma in 
women. 
 Almost all of the subjects evaluated in this study were teachers working in 
public schools. Some previous studies have demonstrated an inverse 
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association of obesity with education status (Kahn and Williamson 1990; Lee 
et al. 2005). Therefore, the high education status of the present population 
might have affected their waist circumference. Other than waist 
circumference, none of the other components of metabolic syndrome was 
extracted as a significant risk factor by logistic regression analysis. These 
results indicate that each of the components of metabolic syndrome had a 
weak association with colorectal adenoma. However, the risk for colorectal 
adenoma increased as more of these components accumulated.  
 
Conclusion 
 In conclusion, although our study was restricted to males, we confirmed that 
metabolic syndrome is a significant risk factor for colorectal adenoma. 
Moreover, we revealed that an increased HOMA-IR value was also a 
significant risk factor for colorectal adenoma, surpassing any of the 
components of metabolic syndrome. The OR for HOMA-IR was comparable to 
that for metabolic syndrome. Hereafter, HOMA-IR should be considered for 
large-scale screening for colorectal adenoma risk, as well as metabolic 
syndrome. HOMA-IR witch calculated from only a fasting blood sample, 
potentially assist to narrow down high risk group of colorectal adenoma. If 
screening colonoscopy intensively performed to highly HOMA-IR group, it 
will grow up cost-effectiveness for colorectal cancer prevention. 
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Table 1. Characteristics of cases with adenoma and controls in male subjects 
Characteristics 
  Control  Adenoma   
P-value 
  (n=702)  (n=261)   
Age (years)   48.8  ± 7.1    52.1  ± 6.0    <0.001※ 
Familial history of CRC (%)   42  (6.4)   15  (6.3)   1.000 
Cigarette smoking status                  
Never (%)   287  (40.9)   106  (40.6)   0.125 
Former (%)   243  (34.6)   76  (29.1)    
Current (%)   172  (24.5)   79  (30.3)    
Smoking (pack-years)   10.9  ± 13.0    12.2  ± 14.4    0.209 
Daily alcohol consumption (g/day)   22.5  ± 29.6    22.0  ± 27.5    0.805 
Use of anti-hypertensive drugs (%)   83  (12.1)   39  (15.8)   0.153 
Use of anti-diabetic drugs (%)   22  (3.1)   11  (4.2)   0.426 
Use of lipid disorder treatment (%)   56  (8.0)   28  (11.1)   0.155 
Use of Aspirin/NSAIDs (%)   18  (2.6)   6  (2.3)   1.000 
BMI (kg/m2)   24.5  ± 3.0    25.1  ± 3.5    0.017※ 
WC (cm)   86.8  ± 7.9    88.6  ± 9.5    0.012 
SBP (mmHg)   121.6  ± 15.3    124.0  ± 15.1    0.020※ 
DBP (mmHg)   77.2  ± 9.7    78.5  ± 9.8    0.059 
FPG (mg/dl)   93.1  ± 31.8    97.8  ± 26.8    <0.001※ 
HbA1c (%)   5.3  ± 0.6    5.5  ± 0.9    <0.001※ 
Insulin (μU/ml)   5.9  ± 4.3    7.2  ± 6.1    <0.001※ 
HOMA-IR   1.4  ± 1.1    1.8  ± 2.1    <0.001※ 
HDL-c (mg/dl)   59.0  ± 14.9    57.4  ± 14.1    0.167 
LDL-c (mg/dl)   130.2  ± 31.8    130.3  ± 32.3    0.835 
Triglycerides (mg/dl)   162.9  ± 106.1    173.5  ± 96.8    0.020※ 
Uric acid (mg/dl)   6.2  ± 1.2    6.2  ± 1.3    0.912 
CRC; colorectal cancer, NSAIDs; non-steroidal anti-inflammatory drugs, BMI; body 
mass index, WC; waist circumference, SBP; systolic blood pressure, DBP; diastolic 
blood pressure, FPG; fasting plasma glucose, HOMA-IR; homeostasis model 
assessment-insulin resistance, HDL-c; high-density lipoprotein-cholesterol, LDL-c; 
low-density lipoprotein-cholesterol. The P-value was given by the chi-square test or 
the Mann-Whitney U-test. ※ P<0.05. 
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Table 2. Characteristics of cases with adenoma and controls in female subjects 
Characteristics 
  Control  Adenoma   
P-value 
  (n=260)  (n=46)   
Age (years)   51.3  ± 6.9    53.2  ± 5.6    0.099 
Menopause (%)   129  (54.2)   31  (73.8)   0.018※ 
Familial history of CRC (%)   19 (7.6)   3 (13.6)   1.000 
Cigarette smoking status                  
Never (%)   241 (92.7)   41 (89.1)   0.286 
Former (%)   16 (6.2)   3 (6.5)    
Current (%)   3 (1.1)   2 (4.4)    
Smoking (pack-years)   1.1  ± 13.0    12.3  ± 14.7    0.331 
Daily alcohol consumption (g/day)   17.6  ± 27.0    19.9  ± 26.7    0.591 
Use of anti-hypertensive drugs (%)   6 (2.3)   1 (14.3)   1.000 
Use of anti-diabetic drugs (%)   18 (7.0)   5 (11.6)   0.347 
Use of lipid disorder treatment (%)   6 (2.3)   1 (14.3)   1.000 
Use of Aspirin/NSAIDs (%)   18 (7.0)   2 (4.4)   0.749 
BMI (kg/m2)   23.1  ± 3.7    23.3  ± 3.4    0.490 
WC (cm)   82.2  ± 10.5    84.0  ± 8.7    0.157 
SBP (mmHg)   113.7  ± 14.5    115.4  ± 18.4    0.886 
DBP (mmHg)   70.9  ± 9.3    72.1  ± 10.6    0.482 
FPG (mg/dl)   88.7  ± 12.5    90.3  ± 1.0    0.110 
HbA1c (%)   5.2  ± 0.5    5.2  ± 0.4    0.558 
Insulin (μU/ml)   4.9  ± 3.3    5.9  ± 4.4    0.267 
HOMA-IR   1.1  ± 0.9    1.4  ± 1.2    0.228 
HDL-c (mg/dl)   72.1  ± 16.4    72.9  ± 17.4    0.658 
LDL-c (mg/dl)   128.6  ± 31.0    135.1  ± 31.9    0.217 
Triglycerides (mg/dl)   103.1  ± 57.7    112.9  ± 68.4    0.396 
Uric acid (mg/dl)   4.7  ± 1.0    5.1  ± 0.9    0.005※ 
CRC; colorectal cancer, NSAIDs; non-steroidal anti-inflammatory drugs, BMI; body 
mass index, WC; waist circumference, SBP; systolic blood pressure, DBP; diastolic 
blood pressure, FPG; fasting plasma glucose, HOMA-IR; homeostasis model 
assessment-insulin resistance, HDL-c; high-density lipoprotein-cholesterol, LDL-c; 
low-density lipoprotein-cholesterol. The P-value was given by the chi-square test or 
the Mann-Whitney U-test. ※ P<0.05. 
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Table 3. The association of the three categories of HOMA-IR with colorectal adenoma in male subjects 
HOMA-IR 
 Control  Adenoma  Univariate  Multivariate† 
 (N=702)  (N=261)   OR 95% C.I. P-value  OR 95% C.I. P-value 
Normal    
502 (71.5) 
  
151 (57.8)  1.00 ref   1.00 ref  
(<1.6)     
    
Intermediate   
128 (18.2) 
  
66 (25.3)  1.71 (1.21-2.43) 0.002※  1.62 (1.07-2.45) 0.003※ 
(>1.6-<2.5)     
  
Insulin resistance   
72 (10.3) 
  
44 (16.9)  2.03 (1.34-3.08) 0.001※  2.23 (1.31-3.79) <0.001※ 
 (>2.5)     
  
Ptrend      
  
<0.001※ 
   
0.001※ 
  
HOMA-IR; homeostasis model assessment-insulin resistance. †adjusted for age, pack-years, daily alcohol 
consumption, familial history of colorectal cancer,  use of anti-diabetic drugs, use of aspirin/NSAIDs, and waist 
circumference. The P-trend was evaluated by entering it into the model as a single variable. ※ P<0.05. 
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Table 4. The association of the three categories of HOMA-IR with colorectal adenoma in female subjects 
HOMA-IR  
Control 
 
Adenoma 
 
Univariate 
 
Multivariate‡ 
 
(N=260) 
 
(N=46) 
 
OR 95% C.I. P-value 
 
OR 95% C.I. P-value 
Normal    
211 (81.2)  35 (76.1)  1.00 ref   1.00 ref  
(<1.6)   
     
Intermediate   
33 (12.7)  5 (10.9)  0.91 (0.33-2.50) 0.860  0.89 (2.4-3.29) 0.865 
(>1.6-<2.5)   
   
Insulin resistance   
16 (6.1)  6 (13.0)  2.26 (0.83-6.17) 0.111  2.20 (4.9-9.85) 0.304 
 (>2.5)         
Ptrend         <0.204       0.458      
HOMA-IR; homeostasis model assessment-insulin resistance. ‡adjusted for age, menopause, pack-years, daily 
alcohol consumption, familial history of colorectal cancer,  use of anti-diabetic drugs, use of aspirin/NSAIDs, and 
waist circumference. The P-trend was evaluated by entering it into the model as a single variable.  
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Table 5. The association of the HOMA-IR, fasting plasma glucose, and insulin levels with the characteristics of 
adenoma in male subjects 
Character N  
HOMA-IR 
 
Fasting Plasma Glucose 
 
Insulin 
 
mean ± S.D. P-value 
 
mean ± S.D. P-value 
 
mean ± S.D. P-value 
Location                 
Each side 224  1.8 ± 1.8 0.642  97.8 ± 27.8 0.966  7.0 ± 5.4 0.632 
Both side  37  2.3 ± 3.0   97.7 ± 19.8   8.7 ± 9.1  
Size                 
<10mm 247  1.7 ± 1.7 0.098  97.9 ± 27.0 0.874  6.9 ± 5.3 0.031※ 
≥10mm 14  3.4 ± 5.5   95.6 ± 23.0   12.2 ± 13.8  
Number                 
1  161  1.7 ± 1.9 0.071  96.5 ± 22.3 0.957  6.6 ± 5.5 0.054 
≥2 101  2.1 ± 2.2   99.8 ± 32.6   8.1 ± 6.8  
The P-value was provided by the Mann-Whitney U test. ※P<0.05  
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Table 6. The association of the HOMA-IR, fasting plasma glucose, and insulin levels with the characteristics of 
adenoma in female 
Character N  
HOMA-IR 
 
Fasting Plasma Glucose 
 
Insulin 
 
mean ± S.D. P-value 
 
mean ± S.D. P-value 
 
mean ± S.D. P-value 
Location 
                
Each side 41 
 
1.4 ± 1.3 0.459 
 
90.8 ± 10.6 0.243 
 
6.0 ± 5.4 0.514 
Both side 5 
 
0.9 ± 0.6 
  
86.0 ± 3.7 
  
4.3 ± 9.1 
 
Size 
                
<10mm 44 
 
1.4 ± 1.2 0.024※ 
 
97.9 ± 10.3 0.402 
 
6.1 ± 4.3 0.022※ 
≥10mm 2 
 
0.3 ± 0.0 
  
95.6 ± 3.5 
  
1.2 ± 0.3 
 
Number 
                
1 34 
 
1.3 ± 1.2 0.271 
 
90.3 ± 8.7 0.310 
 
5.4 ± 4.3 0.169 
≥2 12 
 
1.7 ± 1.2 
  
90.3 ± 14.0 
  
7.1 ± 4.5 
 
The P-value was provided by the Mann-Whitney U test. ※P<0.05 
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Table 7. The association of the components of harmonized metabolic syndrome criteria (2009) with the risk for 
colorectal adenoma in male subjects 
Variables  
Control 
 
Adenoma 
 
Univariate 
 
Multivariate¶ 
 
(N=702) 
 
(N=261) 
 
OR 95% C.I. P-value 
 
OR 95% C.I. P-value 
Central obesity   272 (38.8)  101 (38.7)  1.00 (0.74-1.33) 0.976  0.97 (0.70-1.35) 0.861 
Elevated BP   256 (36.5)  80 (30.7)  0.77 (0.57-1.04) 0.090  0.72 (0.51-1.02) 0.065 
Elevated FPG   125 (17.8)  43 (16.5)  0.91 (0.62-1.33) 0.622  0.95 (0.62-1.45) 0.815 
Reduced HDL-c   282 (40.2)  107 (41.0)  1.03 (0.77-1.38) 0.829  1.12 (0.80-1.58) 0.518 
Elevated TG   91 (13.0)  31 (11.9)  0.90 (0.59-1.40) 0.647  0.95 (0.57-1.57) 0.836 
BP; blood pressure, FPG; fasting plasma glucose, HDL-c; high-density lipoprotein-cholesterol, TG; triglyceride.  
¶analyzed with all components and adjusted for age, smoking status, daily alcohol consumption, and familial 
history of colorectal cancer.  
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Table 8. The association of the components of harmonized metabolic syndrome criteria (2009) with the risk for 
colorectal adenoma in female subjects 
Variables 
  Control  Adenoma  Univariate  Multivariate§ 
  (N=260)  (N=46)  OR 95% C.I. P-value  OR 95% C.I. P-value 
Central obesity   106(40.8)  15(32.6)  0.30 (0.36-1.37) 0.976  0.94 (0.41-2.11) 0.876 
Elevated BP   85(32.7)  19(41.3)  1.45 (0.76-2.76) 0.257  1.78 (0.77-4.14) 0.164 
Elevated FPG   40(15.4)  5(10.9)  0.67 (0.25-1.80) 0.428  0.71 (0.22-2.33) 0.575 
Reduced HDL-c   112(43.1)  20(43.5)  1.02 (0.54-1.91) 0.960  0.72 (0.29-1.78) 0.478 
Elevated TG   41(15.8)  11(23.9)  1.68 (0.79-3.57) 0.179  3.19 (1.19-8.51) 0.021※ 
BP; blood pressure, FPG; fasting plasma glucose, HDL-c; high-density lipoprotein-cholesterol, TG; triglyceride.  
§analyzed with all components and adjusted for age, menopause, smoking status, daily alcohol consumption, and 
familial history of colorectal cancer. ※ P<0.05. 
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Table 9. The association of the number of harmonized metabolic syndrome criteria (2009) with the risk for 
colorectal adenoma in male subjects 
Variables 
  Control  Adenoma  Univariate  Multivariate¶ 
  (N=702)  (N=261)  OR 95% C.I. P-value  OR 95% C.I. P-value 
MS diagnosis   145 (20.7)  86 (33.0)  1.89 (1.38-2.59) <0.001※  1.67 (1.19-2.36) 0.003※ 
MS risk number              
0   211 (30.1)  56 (21.5)  1.00 ref   1.00 ref  
1   201 (28.6)  59 (22.6)  1.02 (0.73-1.67) 0.633  1.04 (0.67-1.61) 0.876 
2   145 (20.7)  60 (23.0)  1.56 (1.02-2.38) 0.039※  1.45 (0.91-2.29) 0.115 
3   93 (13.2)  50 (19.1)  2.04 (1.29-3.19) 0.002※  1.69 (1.03-2.77) 0.036※ 
≥4   52 (7.4)  36 (13.8)  2.61 (1.56-4.38) <0.001※  2.23 (1.28-3.88) 0.005※ 
Ptrend         <0.001※       0.001※     
¶adjusted for age, smoking status, alcohol intake, and familial history of colorectal cancer.  The P trend was 
evaluated by entering it into the model as a single variable. ※ P<0.05. 
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Table 10. The association of the number of harmonized metabolic syndrome criteria (2009) with the risk for 
colorectal adenoma in female subjects 
Variables  
Control 
 
Adenoma 
 
Univariate 
 
Multivariate§ 
 
(N=260) 
 
(N=46) 
 
OR 95% C.I. P-value 
 
OR 95% C.I. P-value 
MS diagnosis   39(15.0)   7(15.2)   1.02  (0.43-2.44) 0.970    0.62 (0.18-2.10) 0.441 
MS risk number              
0   98(37.7)  10(21.7)  1.00 ref   1.00 ref  
1   81(31.2)  19(41.3)  2.30 (1.01-5.22) 0.047※  1.88 (0.70-4.84) 0.213 
2   42(16.2)  10(21.7)  2.33 (0.90-6.02) 0.080  1.96 (0.66-5.84) 0.229 
3   25(9.6)  5(10.9)  1.96 (0.62-6.25) 0.255  1.11 (0.26-4.86) 0.886 
≥4   14(5.3)  2(4.4)  1.40 (0.28-7.06) 0.684  0.57 (0.04-8.74) 0.689 
Ptrend       0.263    0.827   
§adjusted for age, menopause, smoking status, alcohol intake, and familial history of colorectal cancer.  The P 
trend was evaluated by entering it into the model as a single variable. ※ P<0.05. 
 
